Oral clindamycin in the treatment of acute uncomplicated falciparum malaria.
Clinical trials on oral clindamycin as an antimalarial in hospitalized patients and residents of endemic communities were conducted in the Philippines between May 1984 and December 1985. Seven and 9 qualified subjects in hospital were treated with 300 mg (regimen A) and 600 mg (regimen B) respectively, twice daily for 5 days. Eighteen patients seen at a rural health unit were given the lower dosage. On the basis of the 28-day extended in vivo test of WHO, P. falciparum in all but one patient showed susceptibility to the drug as a blood schizontocide hence, the clinical cure of malaria. Side effects were few and self-limiting. Ten other patients on regimen A were cured within the 7- and/or 28-day extended test period. Clindamycin per se is currently one of the few alternatives in the treatment of clinically moderate drug-resistant malaria.
Salazar
N P
NP
Research Institute for Tropical Medicine, Department of Health, Alabang, Muntinlupa, Metro Manila, Philippines.
Saniel
M C
MC
Estoque
M H
MH
Talao
F A
FA
Bustos
D G
DG
Palogan
L P
LP
Gabriel
A I
AI
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D002981:Clindamycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008288:Malaria / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D010270:Parasite Egg Count; D010963:Plasmodium falciparum; D011446:Prospective Studies
D002981:Clindamycin